Developer docs
API playgroundTry for free, no card

Search company profiles

Polaris Pharmaceuticals

Full company profile

uuid0009kfq

Namestring
Polaris Pharmaceuticals
Legal namestring
Polaris Group
Company typeenum
Public
Founded yearint
2006
Descriptiontext

Polaris Pharmaceuticals, operating as Polaris Group (TWSE: 6550), is a Cayman Islands-incorporated clinical-stage biopharmaceutical company founded in 2006 and headquartered in Taipei, with principal R&D operations in San Diego, California. The company is developing ADI-PEG 20 (pegargiminase, brand name ADZODI), a pegylated arginine deiminase biologic that depletes plasma arginine by converting it to citrulline. This selectively starves ASS1-deficient cancer cells, which cannot recycle citrulline back into arginine via the urea cycle, while sparing healthy cells. The lead indication, malignant pleural mesothelioma (MPM), is currently under FDA BLA substantive review following completion of rolling submission in June 2025, with Phase 3 ATOMIC-Meso data showing a four-fold improvement in 36-month survival published in JAMA Oncology. Polaris is also running Phase 2/3 trials in hepatocellular carcinoma, soft tissue sarcoma, and glioblastoma, plus Phase 1 in acute myeloid leukemia (where a 91.3% objective response rate was reported in December 2025) and Phase 2 in NASH.

Polaris operates a dual-engine business model. Engine one is the novel drug development pipeline, monetized through future drug sales and out-licensing to regional commercialization partners — Er-Kim (36 EMEA markets), Bioprofarma Bagó (Argentina/LATAM), and Tabuk (Saudi Arabia + 7 GCC countries). Engine two is a contract development and manufacturing organization (CDMO) business operated through wholly-owned subsidiaries Genovior Biotech Corporation (Taiwan) and DesigneRx Pharmaceuticals (Chengdu, China), which provide peptide API synthesis, sterile injectable fill-finish, and complex injectables to global pharmaceutical customers. Polaris also entered a non-exclusive distribution agreement with MNR Therapeutics in November 2025 for Fulvestrant commercialization in the GCC region.

The company owns three cGMP manufacturing sites: Vacaville, California (biologics manufacturing built in 2005); Chengdu, China (30,000 m² facility established in 2013, FDA/EMA/NMPA compliant); and a new Zhunan, Taiwan plant under construction since April 2025 as part of an NT$80 billion 2025–2029 capacity expansion. Polaris completed a NT$11.76 billion (approximately US$362 million) capital injection in December 2024 and a December 2025 private placement authorization of up to 150 million shares at NT$30 per share, both aimed at funding the dual-engine strategy and the GLP-1 peptide generic opportunity. The company is not yet profitable and does not pay dividends.

Short descriptiontext

Polaris Group is a clinical-stage biopharmaceutical company developing ADI-PEG 20 (pegargiminase), a first-in-class arginine deprivation therapy for ASS1-deficient cancers, with FDA BLA review underway for mesothelioma. It also operates CDMO peptide and sterile injectable manufacturing through its Genovior and DesigneRx subsidiaries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
oncology biopharmaceuticals, arginine deprivation therapy, contract development manufacturing, peptide API manufacturing, sterile injectable fill-finish
Industry3 codes
PRIMARYHLAIACAA
Oncology Specialty Pharmaceuticals
SECONDARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Oncology Biopharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1New Drug Development (ADI-PEG 20)
TypeOne Time License
Description

Polaris is a pre-revenue biopharmaceutical company developing ADI-PEG 20 (pegargiminase) for multiple cancer indications. The lead indication MPM (malignant pleural mesothelioma) is under FDA BLA substantive review. Revenue will come from drug sales upon regulatory approval.

polarispharma.com
2Regional Licensing and Distribution Revenue
TypeLicensing Royalties
Description

Polaris out-licenses ADI-PEG 20 to regional partners (Er-Kim for EMEA, Bioprofarma Bagó for LATAM, Tabuk for GCC) who hold marketing rights and pay licensing fees, milestones, and potentially royalties on net sales.

polarispharma.com
3CDMO Services (Genovior and DesigneRx)
TypeProfessional Services
Description

Contract development and manufacturing services for peptide APIs and sterile injectables through subsidiaries Genovior Biotech Corporation and DesigneRx Pharmaceuticals Chengdu. Generates revenue from manufacturing fees, technology transfer, and contract services for global pharmaceutical customers.

polarispharma.com
4Fulvestrant Commercialization (Genovior/MNR)
TypeTransaction Fee
Description

Genovior (via its parent Polaris Group) has a non-exclusive agreement with MNR Therapeutics for commercialization of Fulvestrant in GCC region, generating product supply and distribution revenue.

polarispharma.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Supply Chain, Infrastructure, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1ADZODI
Description

Brand name for ADI-PEG 20 (pegargiminase) for treatment of malignant pleural mesothelioma

polarispharma.com
Core offering1 text field

Polaris Group is a multinational biopharmaceutical company developing ADI-PEG 20 (Pegargiminase/ADZODI), a first-in-class pegylated arginine deiminase biologic that selectively starves ASS1-deficient cancer cells of arginine. The drug is in late-stage clinical development across multiple oncology indications (malignant pleural mesothelioma, hepatocellular carcinoma, soft tissue sarcoma, glioblastoma, acute myeloid leukemia) and NASH. The company also operates a CDMO business through Genovior Biotech and DesigneRx Pharmaceuticals providing peptide API and sterile injectable contract manufacturing services.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Phase 1 AML trial: 91.3% overall objective response rate (21/23 evaluable patients); 69.6% complete response rate; 19.1 months median overall survival
+3 more records
Product overview1 text field

Polaris Group operates a dual-engine business strategy combining novel cancer drug development with contract manufacturing services. The core product is ADI-PEG 20 (Pegargiminase/ADZODI), a late-stage biologic cancer therapy that works through arginine deprivation. The drug is in FDA review for malignant pleural mesothelioma and undergoing Phase 2/3 trials for multiple other oncology indications including soft tissue sarcoma, glioblastoma, hepatocellular carcinoma, and acute myeloid leukemia. The second engine comprises CDMO operations through Genovior Biotech (peptide API and sterile injectables) and DesigneRx Pharmaceuticals Chengdu (biologics and peptide manufacturing), providing contract development and manufacturing services globally. Manufacturing facilities in California (Vacaville, San Diego) and Chengdu, China operate under FDA, EMA, and NMPA cGMP standards.

Product and service3 records
1ADI-PEG 20 (Pegargiminase/ADZODI)
CategoryOncology Biologic Drug
Description

First-in-class pegylated arginine deiminase biologic that depletes plasma arginine by converting it to citrulline, selectively killing ASS1-deficient cancer cells while sparing healthy cells. In late-stage clinical development for malignant pleural mesothelioma, hepatocellular carcinoma, soft tissue sarcoma, glioblastoma, acute myeloid leukemia, and non-alcoholic steatohepatitis.

2CDMO Services (Contract Development and Manufacturing)
CategoryPharmaceutical CDMO Services
Description

Contract development and manufacturing services for biologics and peptide drugs including process development, scale-up, formulation development, and commercial production under FDA, EMA, and NMPA cGMP standards. Spans clinical sample production to commercial-scale manufacturing for global pharmaceutical customers.

3Fulvestrant
CategoryOncology Distributed Product
Description

Established endocrine therapy for hormone receptor positive (HR+)/HER2-negative advanced breast cancer in postmenopausal women. Supplied by Genovior to MNR Therapeutics for distribution in GCC region.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
1MNR Therapeutics
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-11-21
Description

Genovior (Polaris subsidiary) and MNR Therapeutics (Switzerland) signed a non-exclusive agreement for distribution and commercialization of Fulvestrant in GCC countries. MNR handles market access and hospital channels in GCC while Genovior supplies the product. This expands Polaris's presence in GCC oncology treatment centers.

polarispharma.com
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-07-22
Description

Polaris subsidiary PPI signed exclusive licensing agreement with Bioprofarma Bagó (a fully owned subsidiary of Grupo Empresarial Bagó in Buenos Aires, Argentina) to introduce ADI-PEG 20 (ADZODI) for treatment of MPM to Latin America. PPI develops and manufactures the product while Bioprofarma Bagó holds marketing authorization rights and is responsible for registration, import, and promotion in LATAM.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-04-14
Description

Polaris subsidiary PPI signed exclusive distribution agreement with Er-Kim Pharmaceuticals for commercialization of ADI-PEG 20 (ADZODI) for malignant pleural mesothelioma (MPM) in EMEA (Europe, Middle East, Africa) across 36 markets. Er-Kim is responsible for sales and market access in these territories. The partnership aims to expand access to this innovative metabolic therapy in regions with unmet medical need.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-04-14
Description

Polaris subsidiary PPI signed exclusive partnership with Tabuk Pharmaceuticals (a fully owned subsidiary of Astra Industrial Group in Saudi Arabia) for ADI-PEG 20 (ADZODI) commercialization in Saudi Arabia and 7 GCC countries. Tabuk holds market authorization and handles registration, import, and promotion in the region, which has high unmet medical need for novel cancer therapies.

Strategic tierCoreTypeOthersAnnounced on2023-12-22
Description

Polaris Group acquired 100% of Genovior Biotech Corporation (霖揚生技), a key subsidiary specializing in peptide API and sterile injectable CDMO services. Genovior brings proprietary fully synthetic peptide technology platform and sterile injection formulation capabilities. Its acquisition enables Polaris's dual-engine growth strategy combining novel drug development with CDMO services.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-08-17
Description

Polaris Group partnered with GCAR for inclusion of ADI-PEG 20 in the FDA-accepted GBM AGILE adaptive clinical trial platform. The platform enables simultaneous evaluation of multiple brain cancer drugs with shared control groups. This Phase 2/3 trial targets 300 patients globally and could serve as a direct pathway to regulatory approval.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-11-23
Description

Polaris Group entered a corporate sponsored research agreement with UCI's Vaccine Research Center (led by Dr. Philip Felgner) to support development of Fluvid, a universal mRNA influenza and coronavirus vaccine. Polaris aims to leverage the mRNA vaccine technology for enhanced vaccine and cancer treatment development, targeting to become the first company in Taiwan with mRNA technology capabilities.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-10-06
Description

Polaris Group established a strategic partnership with Nanotein Technologies (San Francisco Bay Area startup) to advance Nanotein's protein-based cell therapy manufacturing solutions. Polaris Group collaborated on cell therapy development leveraging Nanotein's expertise. Nanotein later launched GROW-NK, an NK cell activation and expansion reagent that Polaris Group has strategic interest in.

Recent move12 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Global biologics CDMO offering mammalian and microbial expression and aseptic fill-finish. Comparable to Polaris for recombinant protein manufacturing (relevant to ADI-PEG 20 biologic) and CDMO services.

TypeDirect peer
Description

Korean biologics CDMO with large-scale mammalian cell culture capacity and expanding into peptide and sterile fill-finish. Comparable to Polaris's CDMO business in scope, Asian geography, and customer focus.

TypeDirect peer
Description

Asia-headquartered biologics CDMO with end-to-end capabilities from cell line development to commercial manufacturing. Direct peer to Polaris's Genovior and DesigneRx biologics/peptide CDMO services, with overlapping customer base.

TypeBroad incumbent
Description

World's largest biologics CDMO offering mammalian and microbial expression, peptide manufacturing and fill-finish across global sites. Comparable to Polaris as a biologics/peptide CDMO, though Lonza is far larger and more diversified.

TypeRegional player
Description

Taiwan-based CDMO offering oral solid dose and complex injectables manufacturing with global footprint. Direct regional peer to Polaris/Genovior for Asia-Pacific CDMO services.

TypeDirect peer
Description

Leading peptide API manufacturer serving pharma and biotech customers with both synthetic and recombinant peptide capabilities. Most directly comparable to Genovior's fully synthetic peptide platform and GLP-1 ambitions.

TypeDirect peer
Description

Global CDMO with strong peptide manufacturing and sterile injectable capabilities, including complex formulations. Comparable to Polaris's Genovior platform across peptides and sterile fill-finish.

TypeDirect peer
Description

Switzerland-based peptide CDMO specializing in custom synthesis of therapeutic peptides for clinical and commercial supply. Direct peer to Polaris/Genovior for peptide API and GMP manufacturing.

9Tanvex Biologics
TypeEmerging player
Description

Taiwan-based biologics manufacturer with biosimilar pipeline and US BLA experience. Comparable as a Taiwan-headquartered biologics manufacturer targeting US regulatory approval, though with different therapeutic focus.

TypeEmerging player
Description

Global oncology company headquartered in China with commercial-stage hematology and solid tumor drugs. Comparable as an Asia-rooted oncology developer with global commercial ambitions and manufacturing footprint.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries7 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance10 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Polaris Pharmaceuticals

Oncology Biopharmaceuticalspolarispharma.com

Polaris Group is a clinical-stage biopharmaceutical company developing ADI-PEG 20 (pegargiminase), a first-in-class arginine deprivation therapy for ASS1-deficient cancers, with FDA BLA review underway for mesothelioma. It also operates CDMO peptide and sterile injectable manufacturing through its Genovior and DesigneRx subsidiaries.

What Polaris Pharmaceuticals does

Polaris Pharmaceuticals, operating as Polaris Group (TWSE: 6550), is a Cayman Islands-incorporated clinical-stage biopharmaceutical company founded in 2006 and headquartered in Taipei, with principal R&D operations in San Diego, California. The company is developing ADI-PEG 20 (pegargiminase, brand name ADZODI), a pegylated arginine deiminase biologic that depletes plasma arginine by converting it to citrulline. This selectively starves ASS1-deficient cancer cells, which cannot recycle citrulline back into arginine via the urea cycle, while sparing healthy cells. The lead indication, malignant pleural mesothelioma (MPM), is currently under FDA BLA substantive review following completion of rolling submission in June 2025, with Phase 3 ATOMIC-Meso data showing a four-fold improvement in 36-month survival published in JAMA Oncology. Polaris is also running Phase 2/3 trials in hepatocellular carcinoma, soft tissue sarcoma, and glioblastoma, plus Phase 1 in acute myeloid leukemia (where a 91.3% objective response rate was reported in December 2025) and Phase 2 in NASH.

Polaris operates a dual-engine business model. Engine one is the novel drug development pipeline, monetized through future drug sales and out-licensing to regional commercialization partners — Er-Kim (36 EMEA markets), Bioprofarma Bagó (Argentina/LATAM), and Tabuk (Saudi Arabia + 7 GCC countries). Engine two is a contract development and manufacturing organization (CDMO) business operated through wholly-owned subsidiaries Genovior Biotech Corporation (Taiwan) and DesigneRx Pharmaceuticals (Chengdu, China), which provide peptide API synthesis, sterile injectable fill-finish, and complex injectables to global pharmaceutical customers. Polaris also entered a non-exclusive distribution agreement with MNR Therapeutics in November 2025 for Fulvestrant commercialization in the GCC region.

The company owns three cGMP manufacturing sites: Vacaville, California (biologics manufacturing built in 2005); Chengdu, China (30,000 m² facility established in 2013, FDA/EMA/NMPA compliant); and a new Zhunan, Taiwan plant under construction since April 2025 as part of an NT$80 billion 2025–2029 capacity expansion. Polaris completed a NT$11.76 billion (approximately US$362 million) capital injection in December 2024 and a December 2025 private placement authorization of up to 150 million shares at NT$30 per share, both aimed at funding the dual-engine strategy and the GLP-1 peptide generic opportunity. The company is not yet profitable and does not pay dividends.

Polaris Pharmaceuticals firmographics

Firmographics
Name
Polaris Pharmaceuticals
Legal name
Polaris Group
Website
https://polarispharma.com
Company type
Public
Founded year
2006
Operating status
Operating
Headcount range
11–50 employees
Short description
Polaris Group is a clinical-stage biopharmaceutical company developing ADI-PEG 20 (pegargiminase), a first-in-class arginine deprivation therapy for ASS1-deficient cancers, with FDA BLA review underway for mesothelioma. It also operates CDMO peptide and sterile injectable manufacturing through its Genovior and DesigneRx subsidiaries.
Ownership category
akta.pro rank

Polaris Pharmaceuticals industry classification

Industry
Product category
Oncology Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAA
Oncology Specialty Pharmaceuticals
SECONDARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Oncology biopharmaceuticals
  • Arginine deprivation therapy
  • Contract development manufacturing
  • Peptide API manufacturing
  • Sterile injectable fill-finish

Where Polaris Pharmaceuticals is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices5 records

Markets served

Polaris Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Infrastructure, Personnel, Operations, Marketing or Sales

Revenue model

  1. New Drug Development (ADI-PEG 20): Polaris is a pre-revenue biopharmaceutical company developing ADI-PEG 20 (pegargiminase) for multiple cancer indications. The lead indication MPM (malignant pleural mesothelioma) is under FDA BLA substantive review. Revenue will come from drug sales upon regulatory approval.
  2. Regional Licensing and Distribution Revenue: Polaris out-licenses ADI-PEG 20 to regional partners (Er-Kim for EMEA, Bioprofarma Bagó for LATAM, Tabuk for GCC) who hold marketing rights and pay licensing fees, milestones, and potentially royalties on net sales.
  3. CDMO Services (Genovior and DesigneRx): Contract development and manufacturing services for peptide APIs and sterile injectables through subsidiaries Genovior Biotech Corporation and DesigneRx Pharmaceuticals Chengdu. Generates revenue from manufacturing fees, technology transfer, and contract services for global pharmaceutical customers.
  4. Fulvestrant Commercialization (Genovior/MNR): Genovior (via its parent Polaris Group) has a non-exclusive agreement with MNR Therapeutics for commercialization of Fulvestrant in GCC region, generating product supply and distribution revenue.

Go-to-market motion1 record

Distribution channels5 records

Marketing channels4 records

Polaris Pharmaceuticals product offering

Product offering

Core offering

Polaris Group is a multinational biopharmaceutical company developing ADI-PEG 20 (Pegargiminase/ADZODI), a first-in-class pegylated arginine deiminase biologic that selectively starves ASS1-deficient cancer cells of arginine. The drug is in late-stage clinical development across multiple oncology indications (malignant pleural mesothelioma, hepatocellular carcinoma, soft tissue sarcoma, glioblastoma, acute myeloid leukemia) and NASH. The company also operates a CDMO business through Genovior Biotech and DesigneRx Pharmaceuticals providing peptide API and sterile injectable contract manufacturing services.

Product overview

Polaris Group operates a dual-engine business strategy combining novel cancer drug development with contract manufacturing services. The core product is ADI-PEG 20 (Pegargiminase/ADZODI), a late-stage biologic cancer therapy that works through arginine deprivation. The drug is in FDA review for malignant pleural mesothelioma and undergoing Phase 2/3 trials for multiple other oncology indications including soft tissue sarcoma, glioblastoma, hepatocellular carcinoma, and acute myeloid leukemia. The second engine comprises CDMO operations through Genovior Biotech (peptide API and sterile injectables) and DesigneRx Pharmaceuticals Chengdu (biologics and peptide manufacturing), providing contract development and manufacturing services globally. Manufacturing facilities in California (Vacaville, San Diego) and Chengdu, China operate under FDA, EMA, and NMPA cGMP standards.

Differentiator

Problem solved

Functional benefit

Brands

  • ADZODI: Brand name for ADI-PEG 20 (pegargiminase) for treatment of malignant pleural mesothelioma

Products and services

  • ADI-PEG 20 (Pegargiminase/ADZODI) First-in-class pegylated arginine deiminase biologic that depletes plasma arginine by converting it to citrulline, selectively killing ASS1-deficient cancer cells while sparing healthy cells. In late-stage clinical development for malignant pleural mesothelioma, hepatocellular carcinoma, soft tissue sarcoma, glioblastoma, acute myeloid leukemia, and non-alcoholic steatohepatitis.
  • CDMO Services (Contract Development and Manufacturing) Contract development and manufacturing services for biologics and peptide drugs including process development, scale-up, formulation development, and commercial production under FDA, EMA, and NMPA cGMP standards. Spans clinical sample production to commercial-scale manufacturing for global pharmaceutical customers.
  • Fulvestrant Established endocrine therapy for hormone receptor positive (HR+)/HER2-negative advanced breast cancer in postmenopausal women. Supplied by Genovior to MNR Therapeutics for distribution in GCC region.

Quantifiable outcome

  • Phase 1 AML trial: 91.3% overall objective response rate (21/23 evaluable patients); 69.6% complete response rate; 19.1 months median overall survival
  • +3 more outcomes

Companies that use Polaris Pharmaceuticals

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Polaris Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Polaris Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered minor and core.

  • MNR TherapeuticsminorChannel Partner/ Reseller/ Distributor · 21 November 2025Genovior (Polaris subsidiary) and MNR Therapeutics (Switzerland) signed a non-exclusive agreement for distribution and commercialization of Fulvestrant in GCC countries. MNR handles market access and hospital channels in GCC while Genovior supplies the product. This expands Polaris's presence in GCC oncology treatment centers.
  • Bioprofarma BagócoreChannel Partner/ Reseller/ Distributor · 22 July 2025Polaris subsidiary PPI signed exclusive licensing agreement with Bioprofarma Bagó (a fully owned subsidiary of Grupo Empresarial Bagó in Buenos Aires, Argentina) to introduce ADI-PEG 20 (ADZODI) for treatment of MPM to Latin America. PPI develops and manufactures the product while Bioprofarma Bagó holds marketing authorization rights and is responsible for registration, import, and promotion in LATAM.
  • Er-Kim PharmaceuticalscoreChannel Partner/ Reseller/ Distributor · 14 April 2025Polaris subsidiary PPI signed exclusive distribution agreement with Er-Kim Pharmaceuticals for commercialization of ADI-PEG 20 (ADZODI) for malignant pleural mesothelioma (MPM) in EMEA (Europe, Middle East, Africa) across 36 markets. Er-Kim is responsible for sales and market access in these territories. The partnership aims to expand access to this innovative metabolic therapy in regions with unmet medical need.
  • Tabuk PharmaceuticalscoreChannel Partner/ Reseller/ Distributor · 14 April 2025Polaris subsidiary PPI signed exclusive partnership with Tabuk Pharmaceuticals (a fully owned subsidiary of Astra Industrial Group in Saudi Arabia) for ADI-PEG 20 (ADZODI) commercialization in Saudi Arabia and 7 GCC countries. Tabuk holds market authorization and handles registration, import, and promotion in the region, which has high unmet medical need for novel cancer therapies.
  • Genovior Biotech Corporation (霖揚生技)coreOthers · 22 December 2023Polaris Group acquired 100% of Genovior Biotech Corporation (霖揚生技), a key subsidiary specializing in peptide API and sterile injectable CDMO services. Genovior brings proprietary fully synthetic peptide technology platform and sterile injection formulation capabilities. Its acquisition enables Polaris's dual-engine growth strategy combining novel drug development with CDMO services.
  • Global Coalition for Adaptive Research (GCAR)coreStrategic or Co-development Partner · 17 August 2023Polaris Group partnered with GCAR for inclusion of ADI-PEG 20 in the FDA-accepted GBM AGILE adaptive clinical trial platform. The platform enables simultaneous evaluation of multiple brain cancer drugs with shared control groups. This Phase 2/3 trial targets 300 patients globally and could serve as a direct pathway to regulatory approval.
  • University of California Irvine (UCI) Vaccine Research CenterminorStrategic or Co-development Partner · 23 November 2021Polaris Group entered a corporate sponsored research agreement with UCI's Vaccine Research Center (led by Dr. Philip Felgner) to support development of Fluvid, a universal mRNA influenza and coronavirus vaccine. Polaris aims to leverage the mRNA vaccine technology for enhanced vaccine and cancer treatment development, targeting to become the first company in Taiwan with mRNA technology capabilities.
  • Nanotein TechnologiesminorStrategic or Co-development Partner · 6 October 2021Polaris Group established a strategic partnership with Nanotein Technologies (San Francisco Bay Area startup) to advance Nanotein's protein-based cell therapy manufacturing solutions. Polaris Group collaborated on cell therapy development leveraging Nanotein's expertise. Nanotein later launched GROW-NK, an NK cell activation and expansion reagent that Polaris Group has strategic interest in.

Scale indicators10 records

Recent moves12 records

Expansion highlights5 records

Polaris Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • AGC Biologics: Global biologics CDMO offering mammalian and microbial expression and aseptic fill-finish. Comparable to Polaris for recombinant protein manufacturing (relevant to ADI-PEG 20 biologic) and CDMO services.
  • Samsung Biologics: Korean biologics CDMO with large-scale mammalian cell culture capacity and expanding into peptide and sterile fill-finish. Comparable to Polaris's CDMO business in scope, Asian geography, and customer focus.
  • WuXi Biologics: Asia-headquartered biologics CDMO with end-to-end capabilities from cell line development to commercial manufacturing. Direct peer to Polaris's Genovior and DesigneRx biologics/peptide CDMO services, with overlapping customer base.
  • Bachem Holding AG: Leading peptide API manufacturer serving pharma and biotech customers with both synthetic and recombinant peptide capabilities. Most directly comparable to Genovior's fully synthetic peptide platform and GLP-1 ambitions.
  • CordenPharma: Global CDMO with strong peptide manufacturing and sterile injectable capabilities, including complex formulations. Comparable to Polaris's Genovior platform across peptides and sterile fill-finish.
  • PolyPeptide Group: Switzerland-based peptide CDMO specializing in custom synthesis of therapeutic peptides for clinical and commercial supply. Direct peer to Polaris/Genovior for peptide API and GMP manufacturing.

Broad incumbents

  • Lonza Group: World's largest biologics CDMO offering mammalian and microbial expression, peptide manufacturing and fill-finish across global sites. Comparable to Polaris as a biologics/peptide CDMO, though Lonza is far larger and more diversified.

Regional players

  • Bora Pharmaceuticals: Taiwan-based CDMO offering oral solid dose and complex injectables manufacturing with global footprint. Direct regional peer to Polaris/Genovior for Asia-Pacific CDMO services.

Emerging players

  • Tanvex Biologics: Taiwan-based biologics manufacturer with biosimilar pipeline and US BLA experience. Comparable as a Taiwan-headquartered biologics manufacturer targeting US regulatory approval, though with different therapeutic focus.
  • BeiGene: Global oncology company headquartered in China with commercial-stage hematology and solid tumor drugs. Comparable as an Asia-rooted oncology developer with global commercial ambitions and manufacturing footprint.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Polaris Pharmaceuticals social profiles

Digital presence

Polaris Pharmaceuticals compliance and trust

Trust signal

Compliance10 records

Polaris Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Polaris Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles8 records

Polaris Pharmaceuticals subsidiaries and ownership

Company hierarchy

Subsidiaries7 records

Polaris Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Polaris Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Polaris Pharmaceuticals

What does Polaris Pharmaceuticals do?

Polaris Group is a multinational biopharmaceutical company developing ADI-PEG 20 (Pegargiminase/ADZODI), a first-in-class pegylated arginine deiminase biologic that selectively starves ASS1-deficient cancer cells of arginine. The drug is in late-stage clinical development across multiple oncology indications (malignant pleural mesothelioma, hepatocellular carcinoma, soft tissue sarcoma, glioblastoma, acute myeloid leukemia) and NASH. The company also operates a CDMO business through Genovior Biotech and DesigneRx Pharmaceuticals providing peptide API and sterile injectable contract manufacturing services.

Is Polaris Pharmaceuticals a public or private company?

Polaris Pharmaceuticals is a public company. It is classified as public and is currently operating.

When was Polaris Pharmaceuticals founded?

Polaris Pharmaceuticals was founded in 2006. It employs 11 to 50 people.

Where is Polaris Pharmaceuticals based?

Polaris Pharmaceuticals is headquartered in San Diego, United States, in the North America region.

How does Polaris Pharmaceuticals make money?

Four revenue lines are on record. New Drug Development (ADI-PEG 20) is the primary driver. The others are regional Licensing and Distribution Revenue, CDMO Services (Genovior and DesigneRx) and fulvestrant Commercialization (Genovior/MNR).

Who are Polaris Pharmaceuticals's main competitors?

Direct peers on record are AGC Biologics, Samsung Biologics, WuXi Biologics, Bachem Holding AG, CordenPharma and PolyPeptide Group. Lonza Group is listed as a broad incumbent. Bora Pharmaceuticals is listed as a regional player. Emerging players are Tanvex Biologics and BeiGene.

Does Polaris Pharmaceuticals have an API?

No public API is recorded for Polaris Pharmaceuticals.

What industry is Polaris Pharmaceuticals in?

Polaris Pharmaceuticals's product category is Oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAIACAA, Oncology Specialty Pharmaceuticals, with a secondary code of HLAAAAAH, Therapeutic Peptides & Protein/Peptide Biologics. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comMesothelioma Clinical Trial Pipeline Appears Robust With 45+ Key Pharma Companies Actively Working in the Domain | DelveInsightDelveInsight published its 'Mesothelioma Pipeline Insight 2026' report, identifying 45+ pharmaceutical companies actively developing 50+ pipeline therapies for mesothelioma treatment across various clinical stages. Specific ongoing trials include Genmab's Phase 1/2 study of Rina-S in selected solid tumors including mesothelioma, AstraZeneca's Phase III trial of Volrustomig in unresectable pleural mesothelioma, and Polaris Pharmaceuticals' pegargiminase, which has received Orphan Drug Designation and reached preregistration stage.GlobeNewswireEr-Kim Announces Exclusive Distribution Agreement withEr-Kim Pharmaceuticals signed a distribution agreement with Polaris Pharmaceuticals to commercialize Pegargiminase (ADZODI) across 36 EMEA markets. The enzyme-based cancer drug targets Malignant Pleural Mesothelioma, and Er-Kim is the exclusive partner in certain countries. The drug has already received initial approval in the US.Daily Medical NewsPartnership announces addition of novel cancer-killing biologic to glioblastoma trialA California-based nonprofit and Polaris Pharmaceuticals announced activation of ADI-PEG 20 in the GBM AGILE glioblastoma trial. The trial, opened in July 2019, has screened over 1,500 patients. The biologic depletes arginine to kill cancer cells and will be evaluated at multiple sites.PR NewswireGlobal Malignant Pleural Mesothelioma Industry 2020-2030: Key Marketed and Emerging Drugs in the PipelineResearch and Markets published a market intelligence report on Malignant Pleural Mesothelioma (MPM), covering the 7MM (United States, EU5, and Japan) market from 2017 to 2030. The total MPM therapeutic market was valued at USD 290 million in 2017 across these seven major markets, with the US at USD 112 million, EU-5 at USD 142 million, and Japan at USD 36 million, with growth expected through 2030. The report details currently marketed drugs including Opdivo (Bristol-Myers Squibb/ONO Pharmaceutical) and NovoTTF-100L (NovoCure), as well as multiple pipeline therapies in Phase II/III development from companies including AstraZeneca, Hoffmann-La Roche, Polaris Pharmaceuticals, and PharmaMar.PR NewswirePolaris Announces Drs. James Allison and Padmanee Sharma Joining its Scientific Advisory BoardPolaris Pharmaceuticals, a subsidiary of Polaris Group, announced that Dr. James Allison and Dr. Padmanee Sharma, both leading immunotherapy researchers at MD Anderson Cancer Center, have joined its Scientific Advisory Board. Dr. Allison's foundational research on T cell responses led to the development of ipilimumab, the first FDA-approved drug shown to increase survival in metastatic melanoma patients. The company stated the scientists will help advance ADI-PEG 20, Polaris's lead cancer therapy that works by depleting arginine, an amino acid essential for cancer cell survival.